Eagle Pharmaceuticals, Inc.
NASDAQ:EGRX
4.25 (USD) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 316.61 | 171.546 | 187.802 | 195.892 | 213.312 | 236.707 | 189.482 | 66.227 | 19.099 | 13.679 | 2.539 |
| Cost of Revenue
| 94.936 | 42.18 | 45.465 | 60.897 | 61.916 | 57.186 | 55.306 | 15.647 | 11.714 | 7.381 | 3.166 |
| Gross Profit
| 221.674 | 129.366 | 142.337 | 134.995 | 151.396 | 179.521 | 134.176 | 50.58 | 7.385 | 6.298 | -0.627 |
| Gross Profit Ratio
| 0.7 | 0.754 | 0.758 | 0.689 | 0.71 | 0.758 | 0.708 | 0.764 | 0.387 | 0.46 | -0.247 |
| Reseach & Development Expenses
| 34.088 | 51.275 | 30.785 | 36.81 | 44.419 | 32.607 | 30.262 | 27.855 | 16.816 | 9.796 | 12.805 |
| General & Administrative Expenses
| 98.126 | 66.822 | 75.898 | 73.97 | 57.209 | 73.066 | 37.529 | 15.413 | 5.022 | 0 | 0 |
| Selling & Marketing Expenses
| 8.5 | 8.5 | 2.7 | 2.4 | 3.3 | -1.65 | 14.784 | 4.752 | 4.305 | 0 | 0 |
| SG&A
| 106.626 | 75.322 | 78.598 | 76.37 | 60.509 | 71.416 | 52.313 | 20.165 | 9.326 | 4.958 | 6.399 |
| Other Expenses
| -15.753 | -6.242 | -8.262 | 0.7 | 52.226 | 35.222 | 32.57 | 0 | 0.035 | 0.003 | 0.012 |
| Operating Expenses
| 140.714 | 126.597 | 109.383 | 113.18 | 104.928 | 104.023 | 82.575 | 48.02 | 26.142 | 14.753 | 19.204 |
| Operating Income
| 53.454 | -2.913 | 25.254 | 21.815 | 36.616 | 73.99 | 53.351 | 2.56 | -18.757 | -8.455 | -19.831 |
| Operating Income Ratio
| 0.169 | -0.017 | 0.134 | 0.111 | 0.172 | 0.313 | 0.282 | 0.039 | -0.982 | -0.618 | -7.811 |
| Total Other Income Expenses Net
| 7.979 | -1.635 | -2.577 | 0.183 | -9.852 | -1.508 | 1.75 | 0.014 | -0.538 | 3.001 | -0.039 |
| Income Before Tax
| 61.433 | -4.548 | 22.677 | 21.998 | 34.038 | 72.945 | 53.427 | 2.574 | -19.272 | -6.947 | -20.164 |
| Income Before Tax Ratio
| 0.194 | -0.027 | 0.121 | 0.112 | 0.16 | 0.308 | 0.282 | 0.039 | -1.009 | -0.508 | -7.942 |
| Income Tax Expense
| 25.791 | 4.079 | 10.688 | 7.685 | 2.135 | 21.002 | -28.026 | 0.003 | -1.295 | -0.899 | -0.781 |
| Net Income
| 35.642 | -8.627 | 11.989 | 14.313 | 31.903 | 51.943 | 81.453 | 2.571 | -17.977 | -6.048 | -19.383 |
| Net Income Ratio
| 0.113 | -0.05 | 0.064 | 0.073 | 0.15 | 0.219 | 0.43 | 0.039 | -0.941 | -0.442 | -7.634 |
| EPS
| 2.76 | -0.66 | 0.89 | 1.04 | 2.16 | 3.44 | 5.24 | 0.17 | -1.81 | -0.57 | -1.83 |
| EPS Diluted
| 2.73 | -0.66 | 0.87 | 1.01 | 2.09 | 3.27 | 4.96 | 0.16 | -1.81 | -0.57 | -1.83 |
| EBITDA
| 65.478 | 0.847 | 30.02 | 29.335 | 50.296 | 79.336 | 51.685 | 2.585 | -18.691 | -8.41 | -19.564 |
| EBITDA Ratio
| 0.207 | 0.005 | 0.16 | 0.15 | 0.236 | 0.335 | 0.273 | 0.039 | -0.979 | -0.615 | -7.705 |